Abstract
Purpose :
Digital Eye Strain Diseases are rapid increasing disorders linked to the growing and more prolonged use of video terminals. To date, the only way to mitigate these disorders is using tear substitute or reducing the exposure to the electronic devices. Focus of our research was the development of an eye drop (MDV 2101) based on a specific peptide (MDV PEPTIDE) able to relieve strain of the ocular muscles. Well demonstrated pharmacological activity of the peptide (MDV PEPTIDE) comprises the attenuation of the eye muscle contraction regulating the release of Acetylcholine and so the binding between the neurotransmitter and their receptors in the muscle.
Methods :
MDV 2101 is an isosmotic aqueous solution containing 50 ppm of MDV PEPTIDE in a new and patented Hyaluronic Acid drug delivery system. The stability of the formulation has been executed by means HPLC analysis, Osmolarity and pH changes. The safety of MDV2101 was evaluated by cellular viability using in vitro human corneal cells model (HCE-SkinEthic), through MMT assay.
Results :
We found out that the MDV PEPTIDE in the formulation was stable after 24 months at 25°C, pH and osmolality did not exhibit any variation too. The MMT results after 30 min (irritation test) and 24h (cytotoxicity test) of MDV2101 contact time suggested absence of direct toxicity and no epithelial surface damage (viability >98% versus negative control - PBS).
Conclusions :
MDV2101, safe and stable under our experimental conditions, thanks to the peculiar mechanism of action of MDV PEPTIDE, may be a helpful candidate to relieve Digital Eye Strain Syndrome symptoms.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.